ARDELYX Business Summary

Ardelyx, Inc. (ARDX) is a commercial-stage biopharmaceutical company that generates revenue primarily through the domestic sale of its proprietary, first-in-class medicines and international licensing agreements. The company’s business is bifurcated into two primary segments: Gastrointestinal (GI) health, anchored by IBSRELA (tenapanor) for irritable bowel syndrome with constipation, and Cardio-renal health, led by XPHOZAH (tenapanor) for the management of hyperphosphatemia in chronic kidney disease patients on dialysis. For the full year 2025, Ardelyx reported approximately $378 million in total product revenue, with 2026 guidance projecting IBSRELA sales to reach up to $430 million. The company competes directly with Ironwood Pharmaceuticals (Linzess), Akebia Therapeutics (Auryxia), Bausch Health (Trulance), and Sanofi (Renvela). Ardelyx distinguishes itself as a market disruptor by utilizing its novel NHE3 inhibitor platform to offer a localized, non-systemic mechanism of action that serves as a potent alternative to traditional secretagogues and phosphate binders. Ardelyx was founded in 2007 by Dr. Peter G. Schultz, a renowned chemist and CEO of Scripps Research. The current leadership team is headed by President and CEO Mike Raab, a former partner at New Enterprise Associates with extensive experience in life sciences venture capital. In late 2025, the company strengthened its C-suite by appointing Sue Hohenleitner, formerly of Johnson & Johnson, as Chief Financial Officer, and John Bishop as Chief Technical Operations Officer to oversee scaling manufacturing. Other key executives include Eric Foster (Chief Commercial Officer) and Laura Williams (Chief Patient Officer and Interim CMO). The company is governed by a board chaired by David Mott and maintains a strong institutional investor base, including major positions held by BlackRock, Vanguard, and State Street, reflecting confidence in its trajectory toward a projected $1 billion revenue milestone for IBSRELA by 2029.